Streetbeat News

Products Services

OPTT

Ocean Power Technologies (OPTT) has announced receiving orders for its WAM-V Unmanned Surface Vehicles, totaling over $1.25 million. This significant order intake highlights the growing demand for OPTT's innovative marine technology solutions.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 9:15 pm

RVTY

Revvity, Inc. (NYSE:RVTY) announced the launch of Signals ClinicalTM, a SaaS clinical data science platform designed to centralize clinical trial data for faster insights and decisions, aiming to accelerate the market delivery of therapeutics. Integrated with Spotfire for advanced visual analytics, it promises to enhance efficiency and collaboration in clinical research, potentially transforming the pharmaceutical, biotechnology, and contract research industries.

Portfolio Pulse from Happy Mohamed

February 12, 2024 | 9:09 pm

BIIB

Biogen has received approval from the European Commission for SKYCLARYS, a treatment for Friedreich's ataxia, a rare and debilitating disorder. Clinical trials showed SKYCLARYS improved patient function compared to placebo, marking a significant advancement in treatment for this condition.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 9:07 pm

USDTUSD

Tether CEO Paolo Ardoino, in a recent podcast, expressed optimism about USDT reaching a market cap of $200-$400 billion or even $1 trillion, citing its current $96.5 billion cap and $6.2 billion in 2023 profits. Ardoino highlighted Tether's 100% reserve-backed tokens and a $5.2-billion surplus in corporate reserves. He emphasized the significant usage of USDT in countries like Brazil, Venezuela, Vietnam, and Nigeria, and Tether's focus on blockchain solutions with real-world applications. The article also mentions criticism of stablecoins by New Zealand Central Banker Adrian Orr and U.S. Rep. Maxine Waters' mention of nearing stablecoin regulation in the U.S.

Portfolio Pulse from Khyathi Dalal

February 12, 2024 | 9:05 pm

SQSP

Squarespace has raised its monthly subscription prices by $2-$7 (9-11%) across all four tiers since February 5, leading to a spike in its share price. Analysts have commented positively on this pricing adjustment.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 8:50 pm

BIIB

Biogen (NASDAQ:BIIB) has seen unusual options activity, with a significant bullish sentiment among high-rolling investors, as tracked by Benzinga. The activity includes 11 options trades, with 81% bullish and 18% bearish sentiment, focusing on a price window of $220.0 to $255.0. The largest trades include both put and call options with varying sentiments and expiration dates. Biogen, known for its multiple sclerosis and cancer drugs, has a current market price of $240.98, with neutral RSI indicators and earnings expected in 1 day. Analysts have issued a consensus target price of $282.33, with mixed ratings from UBS and Oppenheimer.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 8:16 pm

RNLX

Renalytix shares surged following the announcement that the Centers for Medicare and Medicaid Services published a draft Local Coverage Determination for KidneyIntelX and kidneyintelX.dkd testing on Feb. 8.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 8:08 pm

V

Oppenheimer analyst Dominick Gabriele reiterated an Outperform rating on Visa Inc. (NYSE:V) with a price target of $297, highlighting the company's potential to benefit from the shift from paper currency to electronic payments. Visa's value-added-service (VAS) growth is expected to remain robust, with a forecasted adjusted EPS of $2.44 for the second quarter. The company's revenue growth was 11.41% in FY23, and its performance is influenced by macroeconomic factors such as interest rates and inflation. Visa's stock has experienced average annual growth of 9.39%, outperforming its peers.

Portfolio Pulse from Nabaparna Bhattacharya

February 12, 2024 | 8:02 pm

LLY

Eli Lilly's weight loss drug, Tripeptide, is gaining market share with BMO Capital Markets tracking its performance. The analyst projects $12.78 billion in revenues for fiscal year 2024. Mounjaro and Zepbound, Eli Lilly's drugs for diabetes and weight loss respectively, have shown significant weekly prescription growth. Despite supply challenges, demand for Eli Lilly's drugs continues to outpace supply, leading BMO to raise its price target for Eli Lilly from $710 to $865. However, LLY shares have recently dropped by 1.16%.

Portfolio Pulse from Vandana Singh

February 12, 2024 | 7:54 pm

GOLD

NEM

Barrick Gold (NYSE:GOLD) announced an increase in proven and probable gold reserves to 77 million ounces by the end of 2023, up from 76 million the previous year. The company, holding a 61.5% stake in Nevada Gold Mines (NGM) through a joint venture with Newmont (NYSE:NEM), highlighted significant contributions from its North American operations, particularly in Northern Nevada, which is described as 'far from being a mature gold district.' Key sites like Carlin, Cortez, and the Turquoise Ridge complex are expected to support production growth for over a decade. Additionally, NGM has initiated a transition to renewable energy with the commissioning of a solar project.

Portfolio Pulse from Stjepan Kalinic

February 12, 2024 | 7:53 pm